Wednesday, April 29, 2020

Glenmark Pharma gets DCGI nod for clinical trials of Favipiravir tablets on COVID-19 patients

Glenmark Pharma gets DCGI nod for clinical trials of Favipiravir tablets on COVID-19 patients Having internally developed the active pharmaceutical ingredients (API) and the formulations for the product, the company filed the product for clinical trials with the DCGI and has received approval for conducting the trial on mild to moderate patients, Glenmark Pharmaceuticals said in a statement.

from Moneycontrol Business News https://ift.tt/2zJWe9B
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

A 'non-event Budget' for stock market: Is that good news for Nifty which fell 1,000 points in January?

As Budget 2026 approaches, analysts expect a low-impact event for equities amid muted expectations. With Nifty already down sharply in Janua...